Dilip Bhat Of Prabhudas Lilladher

News across the web »
Related News »
Dilip Bhat, Joint MD, Prabhudas Lilladher shares his view on Crompton Greaves and Reliance Infra. Bhat told CNBC-TV18, “Crompton Greaves continues to be disappointing on all the fronts whether it is performance, whether it is the margin and ...
May 28, 2012 at 14:27 | Source: MoneyControl.com
SBI is looking attractive at current levels, says Dilip Bhat, Joint MD, Prabhudas Lilladher. Bhat told CNBC-TV18, “SBI has taken it on the chin in a very big way so I think this set of numbers only confirms that possibly the asset quality ...
May 28, 2012 at 10:45 | Source: MoneyControl.com
Dilip Bhat of Prabhudas Lilladher considers Ranbaxy among major stocks on his buy list. In recently issued research report, Emkay Global Financial Services has given a buy call for Ranbaxy with a target price of Rs 559.
May 28, 2012 at 06:27 | Source: Top News India
Global markets will remain in the scary shadow as Europe struggles and the economy festers, says Dilip Bhat, joint managing director at Prabhudas Lilladher. In an interview with Mehul Shah, he says the 50-stock Nifty index could see market rallies ...
May 23, 2012 at 08:42 | Source: Business Standard
“Some key levels to watch out will be 4,765 and eventually the low of 4,530″ he told CNBC TV-18. Even Dilip Bhat of Prabhudas Lilladher echoes a similar sentiment and expects Nifty to fall to 4,500 levels by December. “There could be some ...
May 16, 2012 at 09:05 | Source: firstpost.com